Drug Trial Radar · NCT06034743
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
796
Actual
Start
Nov 22, 2023
Primary completion
May 21, 2025
Study completion Oct 10, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).
Conditions
- Uncontrolled Hypertension
- Resistant Hypertension
Interventions
BaxdrostatDrug
Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths: * 1 mg per tablet for 1 mg baxdrostat Arm; * 2 mg per tablet for 2 mg baxdrostat Arm.
PlaceboDrug
Placebo tablet matching baxdrostat, administered orally, once daily (QD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Seated Systolic Blood Pressure for 2 mg BaxdrostatTime frame: At Week 12
- Change From Baseline in Seated Systolic Blood Pressure for 1 mg BaxdrostatTime frame: At Week 12
Locations
263 sites in 29 countries. Site status is shown where the registry gives one.
Research Site
Saraland, Alabama
Research Site
Scottsdale, Arizona
Research Site
Sun City West, Arizona
Research Site
Surprise, Arizona
Research Site
Little Rock, Arkansas
Research Site
Fresno, California
Research Site
Lincoln, California
Research Site
Orange, California
Research Site
Rancho Cucamonga, California
Research Site
Stanford, California
Research Site
New Haven, Connecticut
Research Site
Clearwater, Florida
Research Site
Jacksonville, Florida
Research Site
Port Orange, Florida
Research Site
Decatur, Georgia
Research Site
East Point, Georgia
Research Site
Springfield, Illinois
Research Site
Munster, Indiana
Research Site
Lexington, Kentucky
Research Site
Detroit, Michigan
Research Site
Rochester, Minnesota
Research Site
Olive Branch, Mississippi
Research Site
Kansas City, Missouri
Research Site
Kansas City, Missouri
Research Site
Kansas City, Missouri
Research Site
Rosedale, New York
Research Site
The Bronx, New York
Research Site
Chapel Hill, North Carolina
Research Site
New Bern, North Carolina
Research Site
Toledo, Ohio
Research Site
Grants Pass, Oregon
Research Site
Bethlehem, Pennsylvania
Research Site
Langhorne, Pennsylvania
Research Site
East Providence, Rhode Island
Research Site
Memphis, Tennessee
Research Site
Brownsville, Texas
Research Site
Corpus Christi, Texas
Research Site
Houston, Texas
Research Site
Sugar Land, Texas
Research Site
Manassas, Virginia
Showing 40 of 263 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.